Compass Therapeutics, Inc.
General ticker "CMPX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $721.1M (TTM average)
Compass Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -27.8%.
Estimated limits based on current volatility of 2.5%: low 2.32$, high 2.44$
Factors to consider:
- Total employees count: 39 (+11.4%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Clinical trial failure, Regulatory and compliance, Commercialization challenges, Capital shortage, Manufacturing supply issues
- Current price 24.8% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.23$, 7.58$]
- 2026-12-31 to 2027-12-31 estimated range: [2.46$, 6.04$]
Financial Metrics affecting the CMPX estimates:
- Positive: with PPE of -12.1 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -5.98 <= 0.28
- Negative: negative Net income
- Negative: -0.75 < Inventory ratio change, % of 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term CMPX quotes
Long-term CMPX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.85MM | $0.00MM |
| Operating Expenses | $50.36MM | $57.48MM | $72.84MM |
| Operating Income | $-50.36MM | $-56.62MM | $-72.84MM |
| Non-Operating Income | $7.87MM | $7.25MM | $6.35MM |
| R&D Expense | $38.12MM | $42.34MM | $55.97MM |
| Income(Loss) | $-42.49MM | $-49.38MM | $-66.49MM |
| Net Income(Loss)* | $-42.49MM | $-49.38MM | $-66.49MM |
| Stockholders Equity | $148.54MM | $125.23MM | $196.79MM |
| Assets | $156.88MM | $140.40MM | $219.59MM |
| Operating Cash Flow | $-40.62MM | $-44.85MM | $-49.14MM |
| Capital expenditure | $0.03MM | $0.04MM | $0.03MM |
| Investing Cash Flow | $26.96MM | $46.77MM | $-93.31MM |
| Financing Cash Flow | $2.94MM | $17.34MM | $129.61MM |
| Earnings Per Share** | $-0.33 | $-0.36 | $-0.42 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.